In a strategic move signaling its growing ambitions, Corona Remedies has acquired seven well-established pharmaceutical brands from Bayer’s Indian portfolio. The acquisition, effective July 16, 2025, includes one cardiology product and six widely used brands in the women’s health and fertility space.
Among the acquired brands is Noklot, a popular antiplatelet medication containing Clopidogrel, used for preventing blood clots in patients with heart disease and post-cardiac procedures.
The women’s health portfolio includes :
Fostine (Urofollitropin): It stimulates ovarian follicles for ovulation in fertility treatments.
Luprofact (Leuprolide acetate): A hormonal therapy used in conditions like endometriosis and for IVF hormone control.
Menodac (Menotropins): A combination of FSH and LH hormones used to induce ovulation and assist in male fertility.
Ovidac (hCG – Human Chorionic Gonadotropin): Commonly used to trigger ovulation and support pregnancy or testosterone production.
Spye (Spiramycin): It is an antibiotic used to treat a parasitic infection known as Toxoplasmosis in pregnant women.
Vageston (Progesterone): Supports early pregnancy and the luteal phase in fertility cycles.
These legacy brands are well-known in India’s gynecology and reproductive health segments, and Corona aims to revitalize their market performance through stronger distribution and marketing networks.
This acquisition comes as Corona Remedies prepares for its Rs 800 crore IPO, filed as an Offer for Sale (OFS) with SEBI in April 2025. The IPO will not include a fresh issue of shares, but will instead allow existing shareholders—including private equity firms like ChrysCapital—to partially exit. The issue will be managed by JM Financial, IIFL Capital, and Kotak Mahindra Capital, with listings planned on both NSE and BSE.
Founded in 2004 and headquartered in Ahmedabad, Corona Remedies has built a portfolio of over 65 brands across key therapeutic areas. It ranked as the second-fastest-growing pharmaceutical company in India (among the top 30) from Dec 2021 to Dec 2024. The company clocked Rs 1,014 crore in revenue in FY24, highlighting its momentum ahead of the public offering.
With this acquisition and IPO, Corona Remedies is positioning itself as a rising force in India’s domestic pharmaceutical space, combining brand consolidation with strategic capital expansion.
